Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Oxford Structural Genomics Consortium (SGC) is a key member of a new EUbOPEN consortium which has been awarded funding from the Innovative Medicines Initiative to develop openly available chemical tools for understanding human biology.

None

The Oxford Structural Genomics Consortium (SGC) is a key member of a new consortium, “Enabling and Unlocking biology in the Open” (EUbOPEN), which has been awarded an Innovative Medicines Initiative grant worth over 66 million Euros. The project will last five years.

The EUbOPEN project builds on the efforts of the successful ULTRA-DD consortium previously led by the University of Oxford, and will be led by Goethe University Frankfurt, and the pharmaceutical company Boehringer Ingelheim. The consortium consists of 22 partners from academia and industry that will work together to develop high quality chemical tools that can be used to investigate the biology of disease and discover new targets for drug discovery. In keeping with the SGC commitment to open science, the project outputs will be made openly available to the research community, without restriction, including chemogenomic library sets, chemical probes, assay protocols and associated research data.

The research at the University of Oxford will be directed by Professor Chas Bountra, the Chief Scientific Officer of SGC Oxford and the University of Oxford’s Pro Vice-chancellor for innovation, and Dr Jon Elkins, Principal Investigator at SGC Oxford.

Read more on the EUbOPEN website

Similar stories

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Research programme tackling COVID-19 variants of concern receives funding boost

A gift from the Red Avenue Foundation will enable the expansion of a major research programme aimed at rapidly identifying and interrogating emerging COVID-19 variants.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.